SLC5A2 and diabetes mellitus: Sodium–glucose cotransporter 2 (SGLT2) inhibitors were originally designed to aid glucose control in patients with diabetes mellitus by blocking SGLT2 in the proximal convoluted tubule of the kidneys, resulting in glucosuria.